My point exactly. By the time IPIX gets up high enough for
My point exactly. By the time IPIX gets up high enough for those of us that haven't bought all our stock in the .20 or lower range to sell to cover our investment then why sell as the risk will have been totally removed from the investment by that time? In fact, the entire risk of IPIX should be resolved within a week or two or three IMO when top line results are given.
IPIX isn't going to rise unless we get excellent human trial results for CV19, then it will rise due to funding inflow that should come about soon after the successful CV trial, then it will rise for a successful UC P2, and so on and so on for a multitude of good things resulting from further B testing. It isn't like IPIX is going to spike and then the shorts/MMs/criminal elements are going to be able to bring the share price back down into the pennies again. Once B gets validated, IPIX is on its climb to being a multi billion dollar company. Might as well stay on for the entire ride and only sell as your lifestyle demands. I think IPIX will be a highly valued stock and I can't see a more safe play to invest my money than staying right here.
Once we know B works good on CV19, then it is obvious it will work on ALL coronaviruses and the value skyrockets.
IMO IPIX is strictly the investment of a lifetime or a complete bust and the odds are next to nil for a complete bust based on the science.
11
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Doughnut-Sized Dilemma for Duolingo Investors Falling stock prices are nothing new, but when Duolingo (NASDAQ: DUOL) tumbles 25.49% and a securities fraud class action tags along, eyebrows raise. Folks invested between May 2, 2025, and February 26, 2026, might want to dig deeper. Why? Because the alleged deception has unraveled any potential optimism these shareholders...
Continue Reading
Purlin's Game-Changer: A Patent in Real Estate Real estate has been chugging along like a stubborn mule, dragging deals through opaque negotiations and haphazard guessing games. Then enters Final Offer from Purlin Enterprises, waving a newly granted patent like a shiny golden ticket to those stuck trading homes in the dark. Leveling the Playing Field with Transparency In...
Continue Reading
A Hot Slice of Legal Trouble for Papa John's Ah, what a steaming mess Papa John's seems to have landed in! And not the good kind with extra cheese. The lawsuit bell tolls for them, reminding investors that even the big guys can get burned. This time, it's for allegedly not having their story straight when it came to market expectations and promotional tactics. Under the...
Continue Reading
Trouble Brewing at DICK'S Sporting Goods Wall Street's not only about the wins. There are moments when the market throws a curveball, and right now, DICK'S Sporting Goods is facing a fast one. DJS Law Group just laid out a class action lawsuit accusing them of bending the securities law rules. It ain't pretty when a company gets tangled up in legal battles, but it's...
Continue Reading
Another Day, Another Lawsuit Nothing says 'start your week' quite like the sounds of courtroom battles echoing across the market landscape. Baidu, Inc. (NASDAQ: BIDU) finds itself in the legal crosshairs, courtesy of the DJS Law Group. They're being accused of some shady dealings, and the core of this drama is all about what they claimed versus the reality of their...
Continue Reading
The AI Agent Arms Race is On Throwdown time in the AI jungle, folks. A new AI agent hit the big 10.9 million downloads in a mere six weeks. In the digital world, those kinds of numbers are the equivalent of finding a unicorn in your backyard. This data gem comes courtesy of Sensor Tower, as reported by Yahoo Finance, and it looks like the appetite for this technological...
Continue Reading
Cranston Climbs Into Scrooge's Shoes for a Cause If you think you've got the holiday season all figured out, add this curveball: Bryan Cranston as Ebenezer Scrooge, jawing through "A Christmas Carol" as part of a unique, one-night-only staged reading. And it's not just another star-studded ploy for attention. It's about rallying around a cause bigger than holiday cheer,...
Continue Reading
Strategic Shift to the Heart of Policy When a healthcare advisory firm decides to root itself in the epicenter of American politics, you know they're gearing up for more than just casual conversation. Jarrard's leap into Washington, D.C. isn't just a relocation—it's an amplification of influence in the complex world of healthcare policy. This move, accentuated by the...
Continue Reading
Alignment or Deception: The M&A Alarm Bells Investors, strap in, because the world of mergers and acquisitions is lighting up like a pinball machine, and today's spotlight's on Varex Imaging Corporation (NASDAQ: VREX), MarineMax (NYSE: HZO), and Synaptics Incorporated (NASDAQ: SYNA). Halper Sadeh LLC, known for their tenacity in championing shareholder rights, has brought...
Continue Reading
Taking Shots at New Mexico's Gun Laws You've got the National Shooting Sports Foundation (NSSF) heading back into the legal trenches. Fresh lawsuit filed, they're targeting New Mexico's Attorney General, Raúl Torrez, for trying to keep a seven-day "cooling off" period intact that they've already been told is unconstitutional. Look, this ain't their first rodeo with this...
Continue Reading
Top 5 Most Recently Viewed Articles
Changes to the Co-Primary Endpoint in the SENTRY Trial Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a pharmaceutical company committed to advancing innovative cancer therapies, has made a crucial adjustment in their Phase 3 SENTRY trial focusing on myelofibrosis. Following valuable feedback from the U.S. Food and Drug Administration (FDA), the company is shifting the...
Continue Reading
First Citizens BancShares Announces Upcoming Earnings Call First Citizens BancShares, Inc. (NASDAQ: FCNCA) has exciting news to share with its investors. The company has officially announced its plan to report financial results for the fiscal quarter that ended June 30, 2025. The announcement is set to be made before the financial markets open on Friday. Details of the...
Continue Reading
Cineverse and Air Bud Entertainment Announce National Talent Search One of Hollywood's Most Enduring Family Film Franchises Returns to Theaters in Summer 2026 Cineverse (NASDAQ: CNVS), a next-generation entertainment studio, alongside Air Bud Entertainment, is thrilled to declare the commencement of a nationwide talent search. This initiative seeks to find the next golden...
Continue Reading
Examining Apple's Position in Technology Hardware In a fast-evolving technology landscape, a thorough analysis of companies is essential for investors and business enthusiasts. This article will explore Apple Inc. (NASDAQ: AAPL) and how it fits into the dynamic Technology Hardware, Storage & Peripherals industry. By analyzing significant financial ratios and market...
Continue Reading
Introducing Vystar’s Revitalized Digital Presence Vystar Corporation (OTCQB: VYST), a leading name in innovative comfort solutions, has taken a bold step forward by launching a freshly redesigned website. With a cleaner look and improved functionality, the new site serves as a vital element of the company's comprehensive digital strategy and brand refresh. Customers can...
Continue Reading